Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clevidipine for Vasospasm After Subarachnoid Hemorrhage
NCT02011321Phase 2Withdrawn
- Sponsor
- Henry Ford Health
- Start
- Mar 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of clevidipine in cerebral vasospasm, sponsored by Henry Ford Health. Primary endpoint: Cerebral blood flow velocity change at 4 hours. Planned start Mar 2014; status: withdrawn.
02
Drugs
clevidipine
03
Conditions
cerebral vasospasm
Beyond the preview
Go deeper on NCT02011321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02011321.